Plasma levels of CX3CL1 (445.13 vs. 397.12 pg/mL, p<0.009) and CCL5 in particular (84.22 vs. 48.72 pg/mL, p<0.0001) were significantly higher compared to healthy controls, while plasma levels of CXCL9 (91.31 vs. 92.92 pg/mL, p<0.4) were not significantly different between breast cancer patients and healthy controls. This evidence concerns the gene CX3CL1 and breast carcinoma.